AxoGen, Inc. develops and markets surgical solutions for peripheral nerve injuries. The company's surgical solutions include Avance Nerve Graft, an off-the-shelf processed human nerve allograft for bridging severed nerves without the comorbidities associated with a second surgical site; AxoGuard Nerve Connector, a porcine submucosa extracellular matrix (ECM) coaptation aid for tensionless repair of severed nerves; and AxoGuard Nerve Protector, a porcine submucosa ECM product that is used to wrap and protect damaged peripheral nerves, as well as reinforces the nerve reconstruction while preventing soft tissue attachments. Its solutions also comprise Avive Soft Tissue Membrane, a minimally processed human umbilical cord membrane that can be used as a resorbable soft tissue covering to separate tissues and modulate inflammation in the surgical bed. In addition, the company offers AcroVal neurosensory and motor testing system, which consists of AcroGrip for use in hand grip strength measurement; AcroPinch for measuring pinch strength; and Pressure-Specified Sensory Device, a somatosensory evaluation and measurement device. Further, it provides AxoTouch two point discriminator, a tool that is used for measuring the innervation density of surface area of the skin. The company provides its products to hospitals, surgery centers, and military hospitals in the United States, Canada, the United Kingdom and other European countries, and internationally. AxoGen, Inc. is headquartered in Alachua, Florida.
Industry, Sector and Symbol
Industry Electromedical equipment
Sub-IndustryN/A
SectorMedical
Phone386-462-6800
Debt
Price-To-Earnings
Sales & Book Value
Annual Sales$60.43 million
Profitability
Miscellaneous
Employees199
OptionableOptionable
AxoGen (NASDAQ:AXGN) Frequently Asked Questions
What is AxoGen's stock symbol?
AxoGen trades on the NASDAQ under the ticker symbol "AXGN."
How were AxoGen's earnings last quarter?
AxoGen, Inc (NASDAQ:AXGN) posted its quarterly earnings data on Monday, October, 29th. The medical equipment provider reported ($0.05) earnings per share for the quarter, hitting analysts' consensus estimates of ($0.05). The medical equipment provider had revenue of $22.66 million for the quarter, compared to analyst estimates of $22.52 million. AxoGen had a negative return on equity of 18.17% and a negative net margin of 25.39%. The company's revenue was up 41.2% on a year-over-year basis. During the same quarter in the prior year, the company earned ($0.04) earnings per share. View AxoGen's Earnings History.
When is AxoGen's next earnings date?
What guidance has AxoGen issued on next quarter's earnings?
AxoGen issued an update on its FY 2018 earnings guidance on Monday, January, 7th. The company provided earnings per share (EPS) guidance of for the period. The company issued revenue guidance of $83.9 million, compared to the consensus revenue estimate of $84.64 million.AxoGen also updated its Q4 2018 guidance to EPS.
What price target have analysts set for AXGN?
6 analysts have issued 12-month target prices for AxoGen's stock. Their forecasts range from $26.00 to $55.00. On average, they expect AxoGen's stock price to reach $41.40 in the next twelve months. This suggests a possible upside of 135.6% from the stock's current price. View Analyst Price Targets for AxoGen.
What is the consensus analysts' recommendation for AxoGen?
6 Wall Street analysts have issued "buy," "hold," and "sell" ratings for AxoGen in the last year. There are currently 1 hold rating and 5 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for AxoGen.
Has AxoGen been receiving favorable news coverage?
News articles about AXGN stock have been trending somewhat negative this week, according to InfoTrie Sentiment. The research firm identifies positive and negative press coverage by analyzing more than six thousand blog and news sources. The firm ranks coverage of companies on a scale of negative five to five, with scores nearest to five being the most favorable. AxoGen earned a media sentiment score of -1.0 on InfoTrie's scale. They also assigned news stories about the medical equipment provider a news buzz of 10.0 out of 10, indicating that recent press coverage is extremely likely to have an impact on the company's share price in the near future.
Who are some of AxoGen's key competitors?
Some companies that are related to AxoGen include CONMED (CNMD), NxStage Medical (NXTM), Natus Medical (BABY), Viewray (VRAY), BioLife Solutions (BLFS), Rockwell Medical (RMTI), Semler Scientific (SMLR), Cutera (CUTR), Helius Medical Technologies (HSDT), Electrocore (ECOR), Zynex (ZYXI), Fonar (FONR), Stereotaxis (STXS), Edap Tms (EDAP) and BioSig Technologies (BSGM).
Who are AxoGen's key executives?
AxoGen's management team includes the folowing people:
- Ms. Karen Zaderej, Chairman, Pres & CEO (Age 57)
- Mr. Peter J. Mariani, Chief Financial Officer (Age 55)
- Mr. Gregory G. Freitag Esq., J.D., CPA, Gen. Counsel & Director (Age 57)
- Mr. Jon S. Gingrich, Chief Commercial Officer (Age 49)
- Mr. Michael Donovan, VP of Operations (Age 54)
Who are AxoGen's major shareholders?
AxoGen's stock is owned by many different of institutional and retail investors. Top institutional investors include BlackRock Inc. (6.78%), Bank of New York Mellon Corp (3.20%), Jennison Associates LLC (2.13%), Baillie Gifford & Co. (1.66%), Peregrine Capital Management LLC (1.13%) and Northern Trust Corp (1.08%). Company insiders that own AxoGen stock include Amy Mcbride Wendell, Gregory Gene Freitag, Guido J Neels, Jamie Mark Grooms, Karen L Zaderej, Robert James Rudelius and Shawn F Mccarrey. View Institutional Ownership Trends for AxoGen.
Which major investors are selling AxoGen stock?
AXGN stock was sold by a variety of institutional investors in the last quarter, including CIBC Private Wealth Group LLC, Bank of America Corp DE, First Trust Advisors LP, Jennison Associates LLC, Advisors Asset Management Inc., Barclays PLC, California Public Employees Retirement System and New York State Common Retirement Fund. Company insiders that have sold AxoGen company stock in the last year include Gregory Gene Freitag, Jamie Mark Grooms, Karen L Zaderej and Shawn F Mccarrey. View Insider Buying and Selling for AxoGen.
Which major investors are buying AxoGen stock?
AXGN stock was acquired by a variety of institutional investors in the last quarter, including Baillie Gifford & Co., Two Sigma Investments LP, Summit Partners Public Asset Management LLC, D. E. Shaw & Co. Inc., Prosight Management LP, Bank of New York Mellon Corp, Peregrine Capital Management LLC and BlackRock Inc.. View Insider Buying and Selling for AxoGen.
How do I buy shares of AxoGen?
Shares of AXGN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is AxoGen's stock price today?
One share of AXGN stock can currently be purchased for approximately $17.57.
How big of a company is AxoGen?
AxoGen has a market capitalization of $673.34 million and generates $60.43 million in revenue each year. The medical equipment provider earns $-10,440,000.00 in net income (profit) each year or ($0.31) on an earnings per share basis. AxoGen employs 199 workers across the globe.
What is AxoGen's official website?
How can I contact AxoGen?
AxoGen's mailing address is 13631 PROGRESS BLVD. SUITE 400, ALACHUA FL, 32615. The medical equipment provider can be reached via phone at 386-462-6800 or via email at [email protected]
MarketBeat Community Rating for AxoGen (NASDAQ AXGN)
MarketBeat's community ratings are surveys of what our community members think about AxoGen and other stocks. Vote "Outperform" if you believe AXGN will outperform the S&P 500 over the long term. Vote "Underperform" if you believe AXGN will underperform the S&P 500 over the long term. You may vote once every thirty days.
